Summit Therapeutics Inc. (SMMT) Stock Analysis — Fair Value, Risk & Moat Rating
NGM · Healthcare · Biotechnology
Is Summit Therapeutics Inc. a safe investment right now?
Trading at $26.38, Summit Therapeutics Inc. (SMMT) in the Healthcare sector does not have sufficient data for a reliable fair value estimate. An Altman Z-Score of 125.07 confirms the company is in the safe zone — financial distress is unlikely near-term. Our moat rating stands at 2.6/5 stars (Narrow moat · eroding), suggesting limited pricing power in a competitive landscape.
Could Summit Therapeutics Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 125.07 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives SMMT's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.8617 | 1.2 | 1.03 |
| B · Retained Earnings / Total Assets | RE / TA | -3.0541 | 1.4 | -4.28 |
| C · EBIT / Total Assets | EBIT / TA | -1.4371 | 3.3 | -4.74 |
| D · Market Cap / Total Liabilities | MCap / TL | 221.7563 | 0.6 | 133.05 |
| E · Revenue / Total Assets | Rev / TA | 0 | 1.0 | 0.0 |
How has SMMT's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 22.8 | Safe |
| 2023 | 82.49 | Safe |
| 2024 | 257.94 | Safe |
| 2025 | 125.07 | Safe |
Source: Calculated from SMMT's latest 10-K filing on SEC EDGAR.
What is Summit Therapeutics Inc. actually worth?
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Summit Therapeutics Inc. have a durable competitive advantage?
Moat rating: 2.6/5.
What makes up SMMT's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is SMMT's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | -11.6% | — |
| 2023 | -336.8% | Declining |
| 2024 | -54.7% | Rising |
| 2025 | -163.8% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Summit Therapeutics Inc.'s dividend safe?
Summit Therapeutics Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | Declining |
| Net Income | −$1.1B | −$0.2B | −$0.1B | Declining |
| Free Cash Flow | −$0.3B | −$0.1B | −$0.0B | Declining |
Common questions about Summit Therapeutics Inc.
Is Summit Therapeutics Inc. at risk of going bankrupt?
Summit Therapeutics Inc.'s Altman Z-Score of 125.07 places it in the safe zone. This metric uses balance sheet ratios to predict bankruptcy probability within 2 years. A score below 1.8 signals distress, while above 3.0 indicates safety.
Why is there no fair value estimate for Summit Therapeutics Inc.?
A reliable fair value estimate requires stable, positive free cash flow or earnings data. This stock may lack sufficient data, or it may be classified as speculative where traditional valuation does not apply.
Does Summit Therapeutics Inc. have a competitive moat?
Summit Therapeutics Inc. receives a moat rating of 2.6 out of 5 stars, based on ROIC stability, gross margin trends, and estimated switching costs. A rating above 3.5 suggests a durable competitive advantage.
Does Summit Therapeutics Inc. pay a dividend?
Summit Therapeutics Inc. does not currently pay a regular dividend, or has suspended its dividend. Check the dividend safety section for the latest status.
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 20, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
SMMT analysis methodology: How we calculate fair value, Z-Scores, and moat ratings